JPWO2021160163A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021160163A5 JPWO2021160163A5 JP2022548122A JP2022548122A JPWO2021160163A5 JP WO2021160163 A5 JPWO2021160163 A5 JP WO2021160163A5 JP 2022548122 A JP2022548122 A JP 2022548122A JP 2022548122 A JP2022548122 A JP 2022548122A JP WO2021160163 A5 JPWO2021160163 A5 JP WO2021160163A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- medicament according
- medicament
- influenza
- coronavirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 39
- 241000700605 Viruses Species 0.000 claims 19
- 241000712431 Influenza A virus Species 0.000 claims 7
- 239000000178 monomer Substances 0.000 claims 7
- 239000003443 antiviral agent Substances 0.000 claims 6
- 239000000539 dimer Substances 0.000 claims 6
- 230000008816 organ damage Effects 0.000 claims 6
- 102000006992 Interferon-alpha Human genes 0.000 claims 5
- 108010047761 Interferon-alpha Proteins 0.000 claims 5
- 238000006471 dimerization reaction Methods 0.000 claims 5
- 210000002889 endothelial cell Anatomy 0.000 claims 5
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 241000711573 Coronaviridae Species 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 229920002306 Glycocalyx Polymers 0.000 claims 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 3
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 claims 3
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 3
- 241000315672 SARS coronavirus Species 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 230000003510 anti-fibrotic effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000003511 endothelial effect Effects 0.000 claims 3
- 210000004517 glycocalyx Anatomy 0.000 claims 3
- 229940113983 lopinavir / ritonavir Drugs 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 208000025721 COVID-19 Diseases 0.000 claims 2
- 241001678559 COVID-19 virus Species 0.000 claims 2
- 241000725619 Dengue virus Species 0.000 claims 2
- 241001115402 Ebolavirus Species 0.000 claims 2
- 241000711950 Filoviridae Species 0.000 claims 2
- 241000710781 Flaviviridae Species 0.000 claims 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 241001115401 Marburgvirus Species 0.000 claims 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 2
- 241000712464 Orthomyxoviridae Species 0.000 claims 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 claims 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims 2
- 241000710886 West Nile virus Species 0.000 claims 2
- 241000710772 Yellow fever virus Species 0.000 claims 2
- 241000907316 Zika virus Species 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- RZVPBGBYGMDSBG-GGAORHGYSA-N baloxavir marboxil Chemical compound COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N([C@H]3c4ccc(F)c(F)c4CSc4ccccc34)n2ccc1=O RZVPBGBYGMDSBG-GGAORHGYSA-N 0.000 claims 2
- 229940008411 baloxavir marboxil Drugs 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims 2
- 229950008454 favipiravir Drugs 0.000 claims 2
- 229960004525 lopinavir Drugs 0.000 claims 2
- 231100000516 lung damage Toxicity 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 229960003752 oseltamivir Drugs 0.000 claims 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims 2
- 229960001084 peramivir Drugs 0.000 claims 2
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical group NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims 2
- 229960000311 ritonavir Drugs 0.000 claims 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 claims 2
- 229960004626 umifenovir Drugs 0.000 claims 2
- 229940051021 yellow-fever virus Drugs 0.000 claims 2
- 229960001028 zanamivir Drugs 0.000 claims 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 2
- AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 claims 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 241000004176 Alphacoronavirus Species 0.000 claims 1
- 241000008904 Betacoronavirus Species 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 101710143544 Griffithsin Proteins 0.000 claims 1
- 206010069767 H1N1 influenza Diseases 0.000 claims 1
- 241000711467 Human coronavirus 229E Species 0.000 claims 1
- 241000482741 Human coronavirus NL63 Species 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000713196 Influenza B virus Species 0.000 claims 1
- 241000713297 Influenza C virus Species 0.000 claims 1
- 208000002979 Influenza in Birds Diseases 0.000 claims 1
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 claims 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 241000700625 Poxviridae Species 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 241000725681 Swine influenza virus Species 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- -1 alisporvir Chemical compound 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 206010064097 avian influenza Diseases 0.000 claims 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical class CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims 1
- 229960003677 chloroquine Drugs 0.000 claims 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 claims 1
- 229960002402 cobicistat Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 229960005107 darunavir Drugs 0.000 claims 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 229960002563 disulfiram Drugs 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 229950002031 galidesivir Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229950004244 laninamivir Drugs 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 claims 1
- 229950009865 nafamostat Drugs 0.000 claims 1
- 229960004378 nintedanib Drugs 0.000 claims 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 1
- 229960002480 nitazoxanide Drugs 0.000 claims 1
- 229960001179 penciclovir Drugs 0.000 claims 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 1
- 229960003073 pirfenidone Drugs 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229960000888 rimantadine Drugs 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 201000010740 swine influenza Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020075408 | 2020-02-14 | ||
CNPCT/CN2020/075408 | 2020-02-14 | ||
CNPCT/CN2020/120662 | 2020-10-13 | ||
CN2020120662 | 2020-10-13 | ||
PCT/CN2021/076519 WO2021160163A1 (en) | 2020-02-14 | 2021-02-10 | Methods for prevention or treatment of virus-induced organ injury or failure with il-22 dimer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023513227A JP2023513227A (ja) | 2023-03-30 |
JPWO2021160163A5 true JPWO2021160163A5 (pt) | 2024-02-16 |
Family
ID=77291386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022548122A Pending JP2023513227A (ja) | 2020-02-14 | 2021-02-10 | Il-22二量体を用いたウイルス誘発性臓器損傷又は不全の予防又は治療方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230079150A1 (pt) |
EP (1) | EP4103219A4 (pt) |
JP (1) | JP2023513227A (pt) |
KR (1) | KR20220164478A (pt) |
CN (1) | CN116670161A (pt) |
AU (1) | AU2021218929A1 (pt) |
BR (1) | BR112022016117A2 (pt) |
CA (1) | CA3166132A1 (pt) |
IL (1) | IL295486A (pt) |
WO (1) | WO2021160163A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
US11510966B2 (en) | 2016-04-15 | 2022-11-29 | Evive Biotechnology (Shanghai) Ltd | Use of IL-22 in treating necrotizing enterocolitis |
WO2023118896A1 (en) * | 2021-12-23 | 2023-06-29 | Subintro Limited | Novel antiviral compositions comprising oleic acid |
WO2024073007A2 (en) * | 2022-09-28 | 2024-04-04 | Napo Pharmaceuticals, Inc. | Lyophilized formulation of crofelemer and methods of treatment using the same |
US11918505B1 (en) * | 2023-09-24 | 2024-03-05 | Baseem Najjar | Penis enlargement device |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102380091A (zh) * | 2010-08-31 | 2012-03-21 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
CN103182072B (zh) * | 2011-12-27 | 2017-05-03 | 健能隆医药技术(上海)有限公司 | 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途 |
WO2014053481A1 (en) * | 2012-10-03 | 2014-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza |
US20160166646A1 (en) * | 2013-06-28 | 2016-06-16 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease |
CN104623637A (zh) * | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
AU2019226085A1 (en) * | 2018-02-21 | 2020-09-17 | Genentech, Inc. | Dosing for treatment with IL-22 Fc fusion proteins |
WO2021207662A1 (en) * | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
-
2021
- 2021-02-10 BR BR112022016117A patent/BR112022016117A2/pt unknown
- 2021-02-10 WO PCT/CN2021/076519 patent/WO2021160163A1/en active Application Filing
- 2021-02-10 US US17/799,627 patent/US20230079150A1/en active Pending
- 2021-02-10 AU AU2021218929A patent/AU2021218929A1/en active Pending
- 2021-02-10 IL IL295486A patent/IL295486A/en unknown
- 2021-02-10 EP EP21753270.4A patent/EP4103219A4/en active Pending
- 2021-02-10 CN CN202180027344.XA patent/CN116670161A/zh active Pending
- 2021-02-10 KR KR1020227031074A patent/KR20220164478A/ko unknown
- 2021-02-10 CA CA3166132A patent/CA3166132A1/en active Pending
- 2021-02-10 JP JP2022548122A patent/JP2023513227A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tian et al. | An update review of emerging small-molecule therapeutic options for COVID-19 | |
Zhirnov et al. | Aprotinin and similar protease inhibitors as drugs against influenza | |
Eggink et al. | Inhibition of HIV-1 by fusion inhibitors | |
JP2010503396A5 (pt) | ||
CA2525202A1 (en) | Use of alpha interferon, ribavirin, dsrna and neuraminidase inhibitors to treat avian influenza | |
CN102268072B (zh) | 流感病毒血凝素蛋白结合多肽的结构和用途 | |
JPWO2021160163A5 (pt) | ||
CN115996741A (zh) | 用于治疗急性呼吸窘迫综合征及病毒感染的cxcr4抑制剂 | |
CN111163792A (zh) | 用于治疗病毒感染的肽 | |
WO2021211808A1 (en) | Compositions and methods to reduce the infectivity of a virus | |
Ashaolu et al. | Potential “biopeptidal” therapeutics for severe respiratory syndrome coronaviruses: a review of antiviral peptides, viral mechanisms, and prospective needs | |
EP4121092A1 (en) | Hybrid interferons for treating viral infections | |
JP2019506840A (ja) | 抗ウイルス剤としてのペプチドおよびこのための使用 | |
US20230233488A1 (en) | Novel use of a modulator of glucosylceramide degradation for viral infections | |
US11376306B2 (en) | Peptides and uses therefor as antiviral agents | |
WO2008004653A1 (fr) | Agent prophylactique ou thérapeutique pour une maladie virale | |
US20230165943A1 (en) | Tp508 acute therapy for patients with respiratory virus infection | |
Michalski et al. | Review of studies on SARS-CoV-2 infection inhibitors | |
Balakrishnan et al. | Peptides with antiviral activities | |
EP3912679A1 (en) | Bbeta-15-42 for the treatment of viral endothelitis | |
EP4268840A2 (en) | Cigb-210 and analogues for the treatment of respiratory infections of viral origin | |
RU2783282C1 (ru) | Противовирусная фармацевтическая композиция, содержащая фавипиравир и аминокислоту, лекарственное средство, ее содержащее, а также их применение для лечения и/или профилактики вирусных инфекций | |
CN105920004B (zh) | 1,2,4-三取代哌嗪化合物在制备抗流感病毒药物中的用途 | |
Priadharsini et al. | Lung Recruitability in COVID-19 | |
WO2022161381A1 (zh) | 血管内皮抑制素在治疗和预防冠状病毒相关疾病中的应用 |